The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Using MRD to analyze the benefit of autologous SCT in patients with myeloma
Susan Bal, MD, UAB School of Medicine, Birmingham, AL, discusses the results from a study which used minimal residual disease (MRD) to evaluate the benefit of autologous stem cell transplant (SCT) in patients with multiple myeloma (MM). Using the available MRD data from the MASTER clinical trial (NCT03224507), Dr Bal explains that testing for MRD with next-generation sequencing allowed researchers to see that patients can still benefit from autologous SCT despite receiving a powerful quadruplet induction of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd). Dr Bal also shares some insights into the role of high-risk cytogenetic abnormalities and how this influenced patient response to SCT following analysis of MRD levels. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
